Alessandra Baldoni

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · Journal of Clinical Oncology · 2020 · 110 citations

Medicine, Oncology, Pharmacology +16

Health-Related Quality of Life in Elderly Patients With Newly Diagnosed Glioblastoma Treated With Short-Course Radiation Therapy Plus Concomitant and Adjuvant Temozolomide

Giuseppe Minniti, Claudia Scaringi, Alessandra Baldoni et al. · International Journal of Radiation Oncology*Biology*Physics · 2013 · 76 citations

Medicine, Oncology, Radiation Oncology +13

Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · Obstetrical & Gynecological Survey · 2021 · 65 citations · Full text

Medicine, Oncology, Pharmacology +15

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

Gennaro Daniele, Domenica Lorusso, Giovanni Scambia et al. · Gynecologic Oncology · 2016 · 43 citations

Medicine, Oncology, Surgery +10